Compare DexCom, Inc. (DXCM) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TeraWulf Inc — how do they compare? DexCom, Inc. trades at $89.03 (market cap $33.79B), while TeraWulf Inc trades at $17.06 (market cap $8.35B). The key difference: DexCom, Inc. is far larger — about 4× TeraWulf Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | WULF | |
|---|---|---|
Market Cap | $33.79B | $8.35B |
Sector | Health | Technology |
52-Week High | $89.53 | $28.98 |
52-Week Low | $54.84 | $5.24 |
Enterprise Value | $33.24B | $10.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
WULF stock trades at $17.69, up 9.2% on the day amid a broader rally in AI infrastructure stocks. The technical picture is bearish with key support at $16 and resistance at $18. Fundamentally, the company reported a Q2 2026 net loss of $1.94 per share, missing estimates, while revenue trends are stable. Despite negative profitability metrics, analyst sentiment remains unanimously bullish with a $38.00 consensus price target, driven by expansion in high-performance computing capacity.
The outlook hinges on execution of its HPC growth strategy, but significant risks include persistent losses, high capital expenditure, and exposure to regulatory shifts. The stock offers high upside if operational targets are met, yet carries substantial volatility and execution risk for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
